Zymeworks (NYSE:ZYME) COO Mark Hollywood Sells 6,120 Shares of Stock

Zymeworks Inc. (NYSE:ZYME) COO Mark Hollywood sold 6,120 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $138,740.40. Following the completion of the sale, the chief operating officer owned 132,913 shares of the company’s stock, valued at approximately $3,013,137.71. The trade was a 4.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zymeworks Price Performance

ZYME opened at $23.92 on Wednesday. Zymeworks Inc. has a fifty-two week low of $9.03 and a fifty-two week high of $28.49. The firm has a market capitalization of $1.79 billion, a P/E ratio of -15.95 and a beta of 1.30. The company’s 50-day moving average is $24.43 and its 200 day moving average is $18.50.

Zymeworks (NYSE:ZYME) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. Zymeworks had a negative net margin of 182.75% and a negative return on equity of 23.00%. The firm had revenue of $27.61 million during the quarter, compared to analyst estimates of $33.69 million. During the same quarter last year, the business posted ($0.39) EPS. The company’s revenue for the quarter was up 72.6% on a year-over-year basis. On average, equities research analysts expect that Zymeworks Inc. will post -1.39 earnings per share for the current year.

Key Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Phase‑3 HERIZON‑GEA‑01 results for Ziihera showed >2 years median overall survival in HER2‑positive GEA and consistent efficacy across PD‑L1 subgroups, with manageable safety. Zymeworks stands to earn up to $440M in milestone payments on approvals — a material revenue upside versus recent quarterly revenue (~$27.6M). This is the primary bullish catalyst supporting the stock move. HERIZON‑GEA‑01 Trial Highlights Zymeworks’ Path To $440M Milestones And Growth
• Neutral Sentiment: Zymeworks announced leadership appointments, promotions and transitions to align with its November corporate strategy — intended to sharpen execution as the company moves from development to potential commercialization. Leadership changes can be positive long term but often create short-term uncertainty. Zymeworks Announces Leadership Appointments and Transitions
• Negative Sentiment: Substantial insider selling occurred on Jan 12: CEO Kenneth Galbraith sold 30,424 shares (~11.8% of his holding), COO Mark Hollywood sold 6,120 shares, EVP Jeffrey Smith sold 9,310 shares, and director/insider Paul A. Moore sold 9,560 shares. Combined, ~55,400 shares were sold for roughly $1.25M at an average price of $22.67. Large, concentrated insider sales can weigh on sentiment and are being closely watched by investors. (CEO filing) CEO SEC Filing (EVP insider alert) Insider Selling: Zymeworks EVP Sells 9,310 Shares

Institutional Investors Weigh In On Zymeworks

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in Zymeworks by 28.9% during the fourth quarter. SG Americas Securities LLC now owns 17,557 shares of the company’s stock valued at $462,000 after purchasing an additional 3,933 shares during the last quarter. Tudor Investment Corp ET AL lifted its stake in shares of Zymeworks by 9.6% during the 3rd quarter. Tudor Investment Corp ET AL now owns 37,583 shares of the company’s stock valued at $642,000 after buying an additional 3,290 shares in the last quarter. PharVision Advisers LLC bought a new position in Zymeworks in the 3rd quarter worth approximately $304,000. Vestal Point Capital LP boosted its holdings in Zymeworks by 53.5% in the 3rd quarter. Vestal Point Capital LP now owns 1,765,000 shares of the company’s stock worth $30,146,000 after buying an additional 615,000 shares during the period. Finally, Quarry LP purchased a new position in Zymeworks in the 3rd quarter valued at approximately $50,000. 92.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ZYME has been the subject of a number of recent analyst reports. B. Riley restated a “buy” rating and issued a $40.00 price objective (up previously from $30.00) on shares of Zymeworks in a research note on Friday, November 21st. Leerink Partners set a $37.00 price target on shares of Zymeworks in a report on Monday, November 17th. Wells Fargo & Company upgraded shares of Zymeworks from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $25.00 to $33.00 in a research report on Friday, December 12th. Citigroup began coverage on shares of Zymeworks in a research report on Wednesday, December 3rd. They issued an “outperform” rating on the stock. Finally, Citizens Jmp initiated coverage on shares of Zymeworks in a research note on Wednesday, December 3rd. They issued a “market outperform” rating and a $32.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $32.82.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, with a focus on the discovery, development and commercialization of multifunctional biotherapeutics. Founded in 2003, the company applies proprietary protein engineering platforms to create novel antibody and protein-based therapies targeting oncology and other serious diseases. Zymeworks is publicly traded on the New York Stock Exchange under the symbol ZYME.

The company’s core technology platforms include Azymetric®, which enables the design of bispecific antibodies capable of engaging two distinct targets simultaneously, and the EFECT™ platform for fine-tuning antibody-drug conjugate properties.